Processa Pharmaceuticals, Inc. Gain (Loss) on Extinguishment of Debt
Processa Pharmaceuticals, Inc. (PCSA) reported Gain (Loss) on Extinguishment of Debt of $5.45 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2017-09-30 was $5.45K.
- Processa Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2017-06-30 was $30.91K, a 22.89% increase year-over-year.
- Processa Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2016-12-31 was -$20.42K.
- Processa Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2016-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2016 was $4.73K.
- Processa Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2014 was -$822.21K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2017-09-30 | $5.45K 10-Q · filed 2017-11-20 | $36.36K derived: sum of 2 quarters · filed 2017-11-20 | $36.36K 10-Q · filed 2017-11-20 | ||
| 2017-06-30 | $30.91K 10-Q · filed 2017-10-04 | $30.91K 10-Q · filed 2017-10-04 | |||
| 2016-12-31 | -$20.42K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$20.42K derived: sum of 2 quarters · filed 2017-11-20 | $4.73K derived: sum of 3 quarters · filed 2017-11-20 | $4.73K 10-K · filed 2017-09-25 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $25.16K derived: sum of 2 quarters · filed 2017-11-20 | $25.16K 10-Q · filed 2017-11-20 | ||
| 2016-06-30 | $25.16K 10-Q · filed 2017-10-04 | $25.16K 10-Q · filed 2017-10-04 | |||
| 2014-12-31 | -$822.21K 10-K · filed 2017-06-19 | $822.21K 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |